Ilaxten: novel non-sedating antihistamine

Ilaxten (bilastine), a second-generation antihistamine for the management of allergic rhinoconjunctivitis and urticaria.

Ilaxten does not cause clinically significant QT-interval prolongation
Ilaxten does not cause clinically significant QT-interval prolongation

(bilastine) is a peripheral H1-receptor antagonist.1

In two phase III, double-blind studies (n=683, n=721), bilastine 20mg was compared with cetirizine 10mg or desloratadine 5mg and placebo once daily for the treatment of seasonal allergic rhinitis. Patients recorded nasal and non-nasal symptoms twice daily; the primary efficacy measure was the area under the curve (AUC) of total symptom score (TSS) over 14 days. In the first trial, bilastine reduced the mean AUC of TSS to a similar extent as cetirizine and to a significantly greater extent than placebo (p<0.001 for bilastine vs placebo).2 In the second trial, similar results were seen when bilastine was compared with desloratadine and placebo (p<0.001 for bilastine vs placebo).3

A third phase III, double-blind study compared the efficacy of bilastine 20mg, levocetirizine 5mg and placebo once daily for 28 days in patients with moderate to severe chronic idiopathic urticaria (n=525). Patients rated symptoms of pruritus, number and maximum size of wheals twice daily. Bilastine reduced mean TSS from baseline to a significantly greater extent than placebo (p<0.001) and displayed similar efficacy to levocetirizine.4


  1. Ilaxten Summary of Product Characteristics, October 2010.
  2. Kuna P et al. Clin Exp Allergy 2009; 39: 1338–47.
  3. Bachert C et al. Allergy 2009; 64: 158–65.
  4. Zuberbier T et al. Allergy 2010; 65: 516–28.

View Ilaxten drug record

Further Information: A. Menarini

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more